{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:01:21Z","timestamp":1782212481630,"version":"3.54.5"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1124\/dmd.32.6.584","type":"journal-article","created":{"date-parts":[[2004,5,20]],"date-time":"2004-05-20T22:28:28Z","timestamp":1085092108000},"page":"584-586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["VALIDATION OF (-)-N-3-BENZYL-PHENOBARBITAL AS A SELECTIVE INHIBITOR OF CYP2C19 IN HUMAN LIVER MICROSOMES"],"prefix":"10.1016","volume":"32","author":[{"given":"Xiaoxin","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina W.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Edom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magang","family":"Shou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. David","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis C.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Baillie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.32.6.584_bib1","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.31.7.815","article-title":"The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.","volume":"31","author":"Bjornsson","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.32.6.584_bib2","first-page":"443","article-title":"The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.","volume":"43","author":"Bjornsson","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.32.6.584_bib3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00003088-200241070-00001","article-title":"Cytochrome P450 phenotyping\/genotyping in patients receiving antipsychotics: useful aid to prescribing?","volume":"41","author":"Dahl","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.32.6.584_bib4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","article-title":"Clinical relevance of genetic polymorphisms in the human CYP2C sub-family.","volume":"52","author":"Goldstein","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.32.6.584_bib5","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1021\/bi00173a017","article-title":"Evidence that CYP2C19 is the major (S)-mephenytoin 4\u2032-hydroxylase in humans.","volume":"33","author":"Goldstein","year":"1994","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.32.6.584_bib6","doi-asserted-by":"crossref","first-page":"12112","DOI":"10.1021\/bi010254c","article-title":"Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19.","volume":"40","author":"Ha-Duong","year":"2001","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.32.6.584_bib7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-2125.2000.00175.x","article-title":"In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.","volume":"49","author":"Ko","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.32.6.584_bib8","first-page":"853","article-title":"Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.","volume":"25","author":"Ko","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.32.6.584_bib9","first-page":"1410","article-title":"Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8, 2C9, and 2C19.","volume":"29","author":"Krausz","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.32.6.584_bib10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1006\/abbi.1998.0615","article-title":"Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin and omeprazole hydroxylations.","volume":"353","author":"Lasker","year":"1998","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.32.6.584_bib11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003088-199835050-00003","article-title":"Inhibition and induction of cytochrome P450 and the clinical implications.","volume":"35","author":"Lin","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.32.6.584_bib12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1124\/dmd.31.4.345","article-title":"Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification.","volume":"31","author":"Lu","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.32.6.584_bib13","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0090-9556(25)06500-6","article-title":"Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes.","volume":"23","author":"Newton","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.32.6.584_bib14","first-page":"465","article-title":"Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochrome P450 and native human liver microsomes.","volume":"57","author":"Rodrigues","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.32.6.584_bib15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2174\/1389200023337522","article-title":"Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences.","volume":"3","author":"Rodrigues","year":"2002","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.32.6.584_bib16","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0090-9556(24)15337-8","article-title":"Selective and potent inhibition of human CYP2C19 activity by a conformationally targeted antipeptide antibody.","volume":"28","author":"Schulz-Utermoehl","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.32.6.584_bib17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/dmd.30.3.235","article-title":"(+)-N-3-benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19.","volume":"30","author":"Suzuki","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.32.6.584_bib18","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1006\/abbi.2000.1835","article-title":"Inhibition selectivity of grapefruit juice components on human cytochromes P450.","volume":"378","author":"Tassaneeyakul","year":"2000","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.32.6.584_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1067\/mcp.2001.116891","article-title":"Optimizing drug development: strategies to assess drug metabolism\/transporter interaction potential-toward a consensus.","volume":"70","author":"Tucker","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.32.6.584_bib20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1124\/dmd.31.3.343","article-title":"Verification of the selectivity of (+)N-3 benzylnirvanol as a CYP2C19 inhibitor.","volume":"31","author":"Walsky","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.32.6.584_bib21","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000028398","article-title":"The CYP2C19 enzyme polymorphism.","volume":"61","author":"Wedlund","year":"2000","journal-title":"Pharmacology"},{"key":"10.1124\/dmd.32.6.584_bib22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0090-9556(24)15373-1","article-title":"CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.","volume":"28","author":"Wester","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.32.6.584_bib23","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1006\/abbi.1993.1506","article-title":"Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4\u2032-hydroxylation.","volume":"306","author":"Wrighton","year":"1993","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.32.6.584_bib24","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3109\/03602539308993982","article-title":"In vitro methods for assessing human hepatic drug metabolism: their use in drug development.","volume":"25","author":"Wrighton","year":"1993","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.32.6.584_bib25","first-page":"897","article-title":"Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro.","volume":"26","author":"Zhang","year":"2001","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624029180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624029180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.32.6.584","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:57:44Z","timestamp":1739897864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624029180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["S0090955624029180"],"URL":"https:\/\/doi.org\/10.1124\/dmd.32.6.584","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"VALIDATION OF (-)-N-3-BENZYL-PHENOBARBITAL AS A SELECTIVE INHIBITOR OF CYP2C19 IN HUMAN LIVER MICROSOMES","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.32.6.584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2004 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}